• Home
• Research
• Specialized Working Groups
• Multiple Myeloma
• Publications

Publications

• Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
  P. Sonneveld, A. Chanan-Khan, K. Weisel, A.K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.V. Mateos, T.M. Mark, M.D. Levin, T. Ahmadi, X. Qin... et al.
  J. Clin. Oncol.: 41(8): 1600-1609 (2023).
  
  
• The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
  G. Palladini, S. Schönland, G. Merlini, P. Milani, A. Jaccard, F. Bridoux, M.A. Dimoopoulos, S. Ravichandran, U. Hegenbart, W. Roeloffzen... P. Sonneveld et al.
  Blood Cancer J.: 13(1): 19 (2023).
  
  
• Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
  E.K. Mai, T. Hielscher, U. Bertsch, H.J. Salwender, S. Zweegman, M.S. Raab, M. Munder, L. Pantani, K. Mancuso, P. Brossart, M. Beksac, I.W. Blau... P. Sonneveld et al.
  Leukemia: 10.1038?s41375-023-02105-6 (2023).
  
  
• Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
  M.A. Dimopoulos, E. Terpos, M. Boccadoro, S. Delimpasi, M. Beksac, E. Katodritou, P. Moreau, L. Baldini, A. Symeonidis, J. Bila, A. Oriol, M.V. Mateos, H. Einsele... P. Sonneveld et al.
  Lancet Haematol.: 10(10): e813-e824 (2023).
  
  
• Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a concensus paper from the European Myeloma Network (EMN)
  E. Terpos, P. Musto, M. Engelhardt, M. Delforge, G. Cook, F. Gay, N.W.C.J. van de Donk, I. Ntanasis-Stathopoulos, A.J. Vangsted, C. Driessen, F. Schjesvold... P. Sonneveld et al.
  Leukemia: (6)1175-1185 (2023).
  
  
• Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
  H. Ludwig, E. Terpos, N. van de Donk, M.V. Mateos, P. Moreau, M.A. Dimopoulos, M. Delforge, P. Rodriguez-Otero, J. San-Miguel, K. Yong, F. Gay, H. Einsele... P. Sonneveld et al.
  Lancet Oncol.: 24(6):e255-e269 (2023).
  
  
• Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
  F. Kraeber-Bodere, S. Zweegman, A. Perrot, C. Hulin, D. Caillot, T. Facon, X. Leleu, K. Belhadj, E. Itti, L. Karlin, C. Bailly, M.D. Levin, M.C. Minnema... P. Sonneveld et al.
  Haemologica: 108(2):621-626 (2023).
  
  
• Population pharmacokinetics and exposure-response analyses of Daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
  A.G. Dosne, X. Li, M.M. Luo, I. Nnane, M.A. Dimopoulos, E. Terpos, P. Sonneveld, T. Kampfenkel, R. Carson, H. Amin, J. Perez Ruixo, H. Zhou, Y.N. Sun, Y. Xu.
  Br. J. Clin. Pharmacol.: 89(5):1640-1655 (2023).
  
  
• Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
  K. Groen, C.A.M. Stege, K. Nasserinejad, K. de Heer, R.J.W. van Kampen, R.B.L. Leys, N. Thielen, M. Wetserman, K.L. Wu, L. Ludwig, D.E. Issa, G.A. Velders... P. Sonneveld et al.
  EClinicalMedicine: 102167 (2023).
  
  
• Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicenter, phase 2 study
  N.W.C.J. van de Donk, M.C. Minnema, B. van der Holt, F. Schjesvold, K.L. Wu, A. Broijl, W.W.H. Roeloffzen, A. Gadisseur, G. Pietrantuono, L. Pour, V.H.J. van der Velden... P. Sonneveld et al.
  Lancet Oncol.: 24(10): 1119-1122 (2023).
  
  
• Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
  C. Bennink, M. de Mul, M. van der Klift, A. Broijl, L. Tick, E. de Jongh, M. Garvelink, D. Lobbezoo, P. Sonneveld, J. Hazelzet.
  Patient.: 16(3): 255-264 (2023).
  
  
• High Hospital-related Costs at the End-of-lif in Patients With Multiple Myeloma: A Single-center Study
  C. Bennink, H. Westgeest, D. Schoonen, F. Boersen, P. Sonneveld, J. Hazelzet, H. Blommestein, M. van der Klift.
  Hemasphere: 7(6): e913.
  
  
• Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus
  E. Terpos, P. Musto, M. Engelhardt, I. Ntanasis-Stathopoulos, P. Sonneveld, H. Ludwig.
  Leukemia: 37(9): 1939-1940 (2023).
  
  
• Melflufen in relapsed/refractory multiple myeloma refractory to prioralkylators: A subgroup analysis from the OCEAN study
  F.H. Schjesvold, H. Ludwig, M.V. Mateos, A. Larocca, H. Abdulhaq, S. Norin, M. Thuresson, N.A. Bakker, P.G. Richardson, P. Sonneveld.
  Eur. J. Haematol.: 10.1111/ejh.14127 (2023).
  
  
• Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
  K. Groen F.H. Schjesvold, B. van der Holt, M.D. Levin, M.R. Seefat, M. Hansson, M.B.L. Leys, J.C. Regelink, A. Waage, D. Szatkowski, P. Axelsson, T. Hieu Do... P. Sonneveld et al.
  Hemasphere: 7(9): e940 (2023).
  
  
• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
  P. Sonneveld, M.A. Dimopoulos, M. Boccadoro, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli... et al.
  N Engl J Med.: 390(4):301-313. doi: 10.1056/NEJMoa2312054 (2024).